Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates 
June 5, 2023

NERVIANO, Italy, June 5, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS Group S.p.A. (NMS group), the largest cancer research and development company in Italy, announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.

NMS is focused on discovery and development of innovative therapies for the treatment of cancer based on proprietary kinase and ADC linker-payload platforms, with approved targeted drugs licensed to pharma companies and proprietary innovative small molecules undergoing clinical studies. The development program will leverage NMS’s proprietary innovative linker-payload platform technology and SolveTx’s antibody-based oncology therapeutics technology. NMS’s linker-payload platform is carefully designed to generate more stable, efficacious, and safer ADCs to treat heterogenous and chemotherapy-resistant solid tumors. The licensed linker-payload includes optimized features; it can be readily conjugated to targeting antibodies, is highly active in preclinical in vitro and in vivo studies, shows bystander activity in heterogeneous tumors, promotes immune system recognition of tumor cells to induce immunogenic cell death, and demonstrates activity in chemotherapy-resistant and poorly proliferating tumors while maintaining a wide therapeutic index.

“We are excited to partner with SolveTx to extend our pipeline beyond our world-famous kinase platform and clinical assets to create novel drugs designed to target tumors more precisely and deliver more potent anticancer agents with our next‑generation linker-payload technology. The SolveTx team has a proven track record of developing transformative anticancer drug candidates and we are pleased that they have selected our linker-payload system for integration into their novel ADCs.” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS and NMS Group.

David Johnson, Founder and Chief Executive Officer of SolveTx, added ”SolveTx is eager to explore use of NMS’s linker-payload as components of our ADCs. We feel that the NMS technology holds promise to overcome the limitations of current linker-payload systems and look forward to rapidly advancing our ADCs to benefit cancer patients in need.”

Under the terms of the agreement, SolveTx will use NMS’s proprietary linker-payload technology to develop novel ADC product candidates for up to four targets selected by SolveTx. SolveTx will be responsible for the generation of targeting antibodies and all nonclinical, clinical, and commercialization activities relating to any resulting product candidates.

Link: NMS-SolveTx PR NMS Press release 05 June 2023

from NMSGroup


Welcome and Check out our new motion picture!